Cyclica offers an integrated proteome-wide drug discovery platform that applies structure-based, AI-augmented in silico methods to polypharmacology. Its core products include Ligand Design and Ligand Express, powered by MatchMaker™, a deep-learning proteome screening technology, and POEM™, a supervised learning tool for predicting molecular properties. The platform is designed to prioritize novel, drug-like chemical matter based on on- and off-target polypharmacological profiles and developmental properties. The company plans to use new funding to continue innovation on its platform and to expand application within the pharmaceutical industry and into adjacent sectors such as agro-chemicals. Cyclica is accelerating a commercial strategy to create and own hundreds of drug discovery programs via spin-outs and joint ventures, facilitated by its Cyclica Academic Partnership Program (CAPP). Recent collaborations cited include EntheogeniX Biosciences, NineteenGale Therapeutics, Rosetta Therapeutics, the Rare Diseases Medicine Accelerator, a joint venture with Mannin Research, and two stealth JVs encompassing over 50 programs. Cyclica provides a predictive analytics platform designed to evaluate and compare small molecules and predict how each will interact with the human proteome. Its platform currently includes PROBEx (proteome-docking), SWITCHx (ligand effect prediction) and DIVEx (systems biology and drug-protein interactomes). The company intends to use new funding to scale sales and marketing efforts and to expand innovation through continued product development. Cyclica completed a $2.4M financing (Series A1) to support these initiatives. The company is led by President and CEO Naheed Kurji. The product is positioned to augment drug discovery pipelines and advance assets toward the bedside. Cyclica Inc. is a Toronto-based startup that uses big data and applied analytic techniques to increase productivity in pharmaceutical research and development. Led by CEO Paul Angelico, the company develops pharmaceutical drugs, nutraceutical ingredients, and personal care products using its proprietary Ligand Express™ computational analysis platform. Ligand Express simulates the interaction of compounds with all known human proteins to assess safety, efficacy and cross-reactivity. Through a partnership with IBM Research, Cyclica is creating vast stores of proprietary data to support its analyses. The company has received seed funding from GreenSky Accelerator Fund I and is still accepting angel investment; the amount was not disclosed. Cyclica said the seed proceeds will be used to accelerate growth.

Total raised

$19M

Funding rounds

3

Latest round

Series B

Latest activity

Jun 2020